Twist Bioscience Reports Director Changes and Compensation Adjustments

Ticker: TWST · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1581280

Twist Bioscience Corp 8-K Filing Summary
FieldDetail
CompanyTwist Bioscience Corp (TWST)
Form Type8-K
Filed DateAug 6, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, compensation, governance

TL;DR

Twist Bioscience shakes up board, adjusts exec pay. Big changes coming?

AI Summary

Twist Bioscience Corporation announced on August 5, 2025, changes in its board of directors and executive compensation. Specifically, the company elected new directors and adjusted compensatory arrangements for certain officers. The filing also includes financial statements and exhibits.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board and executive compensation can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

  • Twist Bioscience Corporation (company) — Registrant
  • August 5, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 681 Gateway Boulevard (address) — Principal executive offices
  • South San Francisco, CA 94080 (address) — Principal executive offices

FAQ

What specific changes were made to the board of directors?

The filing indicates the election of new directors, but the specific names and details of their appointments are not provided in this excerpt.

What are the details of the compensatory arrangements for certain officers?

The filing mentions adjustments to compensatory arrangements for certain officers, but the specific details of these arrangements are not included in this summary.

What is the SIC code for Twist Bioscience Corp?

The Standard Industrial Classification (SIC) code for Twist Bioscience Corp is 2836, for Biological Products (No Diagnostic Substances).

When is Twist Bioscience Corporation's fiscal year end?

Twist Bioscience Corporation's fiscal year ends on September 30.

What is the purpose of this Form 8-K filing?

This Form 8-K is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on the departure of directors, election of directors, appointment of officers, and compensatory arrangements, as well as financial statements and exhibits.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Twist Bioscience Corp (TWST).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.